লোডিং…
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
BACKGROUND: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Approaches to combine immunotherapies and targeted therapies to overcome or delay drug r...
প্রধান লেখক: | , , , , , , , , , , , , , , , , |
---|---|
বিন্যাস: | Online প্রবন্ধ পাঠ্য |
ভাষা: | English |
প্রকাশিত: |
BioMed Central
2019
|
বিষয়গুলি: | |
অনলাইন ব্যবহার করুন: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617639/ https://www.ncbi.nlm.nih.gov/pubmed/31291990 http://dx.doi.org/10.1186/s40425-019-0643-8 |